FY2025 EPS Estimates for Amgen Inc. (NASDAQ:AMGN) Reduced by Analyst

Amgen Inc. (NASDAQ:AMGN) – Analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Amgen in a note issued to investors on Wednesday, April 17th. William Blair analyst M. Phipps now forecasts that the medical research company will post earnings of $19.15 per share for the year, down from their prior forecast of $19.34. The consensus estimate for Amgen’s current full-year earnings is $19.45 per share.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.09 EPS.

Other research analysts have also issued research reports about the company. Oppenheimer reissued an “outperform” rating and set a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Royal Bank of Canada restated an “outperform” rating and issued a $329.00 price objective on shares of Amgen in a research report on Wednesday, April 3rd. Truist Financial restated a “buy” rating and issued a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. TD Cowen decreased their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Raymond James began coverage on shares of Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating on the stock. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Stock Up 2.4 %

AMGN stock opened at $268.93 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The firm has a market capitalization of $144.12 billion, a PE ratio of 21.53, a PEG ratio of 2.46 and a beta of 0.58. Amgen has a twelve month low of $211.71 and a twelve month high of $329.72. The stock has a 50-day simple moving average of $276.90 and a two-hundred day simple moving average of $281.26.

Institutional Trading of Amgen

A number of institutional investors have recently made changes to their positions in the stock. Maryland State Retirement & Pension System boosted its stake in shares of Amgen by 0.9% during the first quarter. Maryland State Retirement & Pension System now owns 41,945 shares of the medical research company’s stock valued at $11,103,000 after purchasing an additional 356 shares during the period. Cohen Investment Advisors LLC lifted its stake in Amgen by 4.1% in the first quarter. Cohen Investment Advisors LLC now owns 9,795 shares of the medical research company’s stock worth $2,785,000 after acquiring an additional 382 shares during the period. Everett Harris & Co. CA lifted its stake in Amgen by 11.0% in the first quarter. Everett Harris & Co. CA now owns 25,023 shares of the medical research company’s stock worth $7,115,000 after acquiring an additional 2,474 shares during the period. Veracity Capital LLC lifted its stake in Amgen by 8.2% in the first quarter. Veracity Capital LLC now owns 1,614 shares of the medical research company’s stock worth $459,000 after acquiring an additional 123 shares during the period. Finally, Marshall Financial Group LLC lifted its stake in Amgen by 9.3% in the first quarter. Marshall Financial Group LLC now owns 3,590 shares of the medical research company’s stock worth $1,021,000 after acquiring an additional 306 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.